Andrew Berens
Stock Analyst at Leerink Partners
(1.39)
# 3,158
Out of 4,818 analysts
123
Total ratings
45.45%
Success rate
-10.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $2.07 | +189.86% | 3 | Apr 2, 2025 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $28.37 | +97.39% | 11 | Sep 27, 2024 | |
| CELC Celcuity | Initiates: Outperform | $29 | $11.12 | +160.79% | 1 | Jul 22, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $85.93 | +12.88% | 24 | May 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $4.47 | +347.43% | 4 | Jan 5, 2023 | |
| ARVN Arvinas | Maintains: Outperform | $74 → $70 | $9.07 | +671.78% | 5 | Nov 23, 2022 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $68.51 | +15.31% | 12 | Nov 14, 2022 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $36 → $25 | $8.41 | +197.44% | 3 | May 13, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | $40 | $5.79 | +590.85% | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $67 | $1.63 | +4,023.08% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $1 | $0.38 | +163.99% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.73 | +1,108.79% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $12.45 | +100.80% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $106.38 | -9.76% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $69 → $110 | $72.71 | +51.29% | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $58.00 | +34.48% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $41.83 | +14.75% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $11.68 | +139.73% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.50 | +1,700.00% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $0.78 | +3,746.15% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $5.33 | +275.23% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $1.49 | +1,577.85% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $7.85 | +1.98% | 7 | Jul 14, 2017 |
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $2.07
Upside: +189.86%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $28.37
Upside: +97.39%
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $11.12
Upside: +160.79%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $85.93
Upside: +12.88%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $4.47
Upside: +347.43%
Arvinas
Nov 23, 2022
Maintains: Outperform
Price Target: $74 → $70
Current: $9.07
Upside: +671.78%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $68.51
Upside: +15.31%
Cullinan Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $8.41
Upside: +197.44%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $5.79
Upside: +590.85%
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $1.63
Upside: +4,023.08%
Mar 21, 2025
Downgrades: Market Perform
Price Target: $9 → $1
Current: $0.38
Upside: +163.99%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.73
Upside: +1,108.79%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $12.45
Upside: +100.80%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $106.38
Upside: -9.76%
Apr 1, 2024
Upgrades: Outperform
Price Target: $69 → $110
Current: $72.71
Upside: +51.29%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $58.00
Upside: +34.48%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $41.83
Upside: +14.75%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $11.68
Upside: +139.73%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.50
Upside: +1,700.00%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $0.78
Upside: +3,746.15%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $5.33
Upside: +275.23%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $1.49
Upside: +1,577.85%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $7.85
Upside: +1.98%